Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNX80 in Intermittent Claudication
NCT05400395Phase 4Unknown
- Sponsor
- SK Chemicals
- Start
- Sep 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Vasoclean in intermittent claudication (IC) (2 arms), sponsored by SK Chemicals. Primary endpoint: Walking Distance at 24 weeks. Status: unknown.
02
Drugs
Vasoclean
03
Conditions
intermittent claudication (IC)
Beyond the preview
Go deeper on NCT05400395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400395.